14 Results

People

  1. Brogi
    Brogi
  2. Modi
    Modi
  3. Wen
    Wen
  4. Castillo
    Castillo
  5. Goldman
    Goldman
  6. Gonen
    Gonen
  7. Jhaveri
    Jhaveri
  8. Ross
    Ross
  9. Ulaner
    Ulaner
  10. Ventura
    Ventura

Groups

  1. Department of Medicine (10)
  2. Solid Tumor Oncology Division (10)
  3. Breast Medicine Service (7)
  4. Biostatistics Service (3)
  5. Department of Pathology and Laboratory Medicine (3)
  6. Epidemiology and Biostatistics (3)
  7. Center for Pancreatic Cancer Research (2)
  8. Gastrointestinal Oncology Service (2)
  9. Molecular Imaging and Therapy Service (2)
  10. Radiology, Department of (2)
  1. "human epidermal growth factor receptor 2"
Formats
  1. Journal Article (11)
  2. Review (2)
  3. Book Section (1)
Groups
  1. Department of Medicine (10)
  2. Solid Tumor Oncology Division (10)
  3. Breast Medicine Service (7)
  4. Biostatistics Service (3)
  5. Department of Pathology and Laboratory Medicine (3)
  6. Epidemiology and Biostatistics (3)

More Groups

People
  1. Edi Brogi (3)
  2. Hannah Wen (3)
  3. Shanu Modi (3)
  4. Dara Ross (2)
  5. Debra Goldman (2)
  6. Gary Ulaner (2)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2022 (1)
  4. 2021 (2)
  5. 2019 (2)
  6. 2017 (2)

More Years

Publications
  1. European Journal of Nuclear Medicine and Molecular Imaging (2)
  2. Future Oncology (2)
  3. Advances in Therapy (1)
  4. Breast (1)
  5. Breast Cancer Research and Treatment (1)
  6. Breast Journal (1)

More Publications

Publishers
  1. Springer (5)
  2. Wiley Blackwell (3)
  3. Future Medicine (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Inc. (1)
  6. European Society for Medical Oncology (1)

More Publishers

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
    Journal Article

    Rugo, H. S.; Bardia, A.; Gradishar, W. J.; Hamilton, E. P.; Hurvitz, S. A.; Jhaveri, K.; Mahtani, R.; Tolaney, S. M.
    Breast (2025)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: A pooled analysis of two phase I studies
    Journal Article

    Takahashi, S.; Bando, H.; Kinoshita, I.; Modi, S.; Tsurutani, J.; Bang, Y. J.; Sato, Y.; Nakatani, S.; Lee, C.; Sugihara, M.; more...
    Japanese Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
    Review

    Curigliano, G.; Dent, R.; Earle, H.; Modi, S.; Tarantino, P.; Viale, G.; Tolaney, S. M.
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab in patients with non-breast/gastroesophageal HER2-amplified tumors: Results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol J
    Journal Article

    Connolly, R. M.; Wang, V.; Hyman, D. M.; Grivas, P.; Mitchell, E. P.; Wright, J. J.; Sharon, E.; Gray, R. J.; McShane, L. M.; Rubinstein, L. V.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Early-stage triple-negative breast cancer
    Book Section

    Traina, T. A.; dos Anjos, C.; Walsh, E.
    In Abutalib, S. A.; Markman, M.; Benson, A. B. 3rd; Rugo, H. S. (Eds.) Cancer Consult: Expertise in Clinical Practice (2024)

    Fulltext@MSK | Save
  • HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
    Review

    Tabernero, J.; Shen, L.; Elimova, E.; Ku, G.; Liu, T.; Shitara, K.; Lin, X.; Boyken, L.; Li, H.; Grim, J.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: A focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline
    Journal Article

    Hoda, R. S.; Bowman, A. S.; Zehir, A.; Razavi, P.; Brogi, E.; Ladanyi, M.; Arcila, M. E.; Wen, H. Y.; Ross, D. S.
    Histopathology (2021)

    Fulltext@MSK | Save
  • First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
    Journal Article

    Chung, H. C.; Bang, Y. J.; Fuchs, C. S.; Qin, S. K.; Satoh, T.; Shitara, K.; Tabernero, J.; Cutsem, E. V.; Alsina, M.; Cao, Z. A.; more...
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system
    Journal Article

    Yoon, E. C.; Schwartz, C.; Brogi, E.; Ventura, K.; Wen, H.; Darvishian, F.
    Breast Journal (2019)

    Fulltext@MSK | Save
  • Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Journal Article

    Krystel-Whittemore, M.; Xu, J.; Brogi, E.; Ventura, K.; Patil, S.; Ross, D. S.; Dang, C.; Robson, M.; Norton, L.; Morrow, M.; more...
    Breast Cancer Research and Treatment (2019)

    Fulltext@MSK | Save